JP Morgan starts Lexeo at overweight, sees upside with continued de-risking (NASDAQ:LXEO)

Mikko Lemola/iStock via Getty Images

JP Morgan has started coverage of newly public Lexeo Therapeutics (NASDAQ:LXEO) with an overweight rating, stating it saw potential upside with continued de-risking of its drug candidates.

The investment bank said it believes the company’s lead drug candidate LX2006 provides

Source link

Related Articles

Back to top button